Clinical Trial Update: First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line bevacizumab, carboplatin, and paclitaxel in stage III-IV ovarian, primary peritoneal, and fallopian tube cancer has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Fallopian Tube Clear Cell Adenocarcinoma
• Fallopian Tube Endometrioid Adenocarcinoma
• Fallopian Tube Mucinous Adenocarcinoma
• Fallopian Tube Serous Adenocarcinoma
• Fallopian Tube Transitional Cell Carcinoma
• Fallopian Tube Undifferentiated Carcinoma
• Ovarian Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-06-10